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Abstract
Background: Vitamin A supplementation significantly reduces all-cause mortality when given between 6–59 months
of age, but has a null or detrimental effect when given between 1–5 months. Studies of neonatal vitamin A
supplementation conducted across Africa and South Asia have produced conflicting findings. These age-pattern
variations might result from immunological interactions between vitamin A supplementation and vaccines.
Knowledge on the potential immunological sequelae of human neonatal vitamin A supplementation is so scarce
that the foremost aim of this study is to seek indicative data on aspects of immunity likely to be affected by
neonatal vitamin A supplementation. The objective of this trial is to test whether human neonatal vitamin A
supplementation modulates immune function including improved thymic maturation in infancy and improved
systemic immune responses to routine immunization.
Methods/design: In an area of moderate vitamin A deficiency in a peri-urban area of The Gambia, 200 mother–infant
pairs were enrolled in a double-blind randomised controlled trial. Within 48 hours of birth, neonates were randomised
with stratification by birth weight and sex to receive either an oral dose of 50,000 IU vitamin A or placebo. Expanded
Programme of Immunisation birth vaccinations were administered after supplementation, with subsequent vaccinations
administered at 8, 12 and 16 weeks of age. A range of immunological outcomes were examined up to 17 weeks of age,
with additional morbidity and anthropometry follow-up carried out throughout the first year of life. The primary
endpoint of this trial is the frequency of circulating T regulatory (Treg) cells expressing gut homing receptors in infants at
17 week post-supplementation, with secondary outcomes including thymus maturation and B cell immune responses.
Discussion: Indicative immunological data from this trial (and its Bangladeshi counterpart), will complement the larger
randomised controlled trials (conducted in India, Tanzania and Ghana), on the effectiveness and safety of neonatal
vitamin A supplementation in improving infant survival. Combined these trials, in addition to the existing trials, will
inform policy.
Trial registration: clinicaltrials.gov NCT01476358
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Background
Within Africa and South-East Asia, vitamin A defi-
ciency (VAD) (defined as a serum retinol concentra-
tion < 0.70 μmol/l), affects > 19 million pregnant
women and 190 million children aged under 5 years [1].
This deficiency is a major contributor to eye disorders and
mortality [2]. To reduce these risks, the world health
organization (WHO) recommends administering periodic
high-dose vitamin A (VA) supplements to children aged
6–59 months living in low-income countries, as at the
time of policy formation this intervention had been shown
to reduce all cause mortality by 23 to 30% in this age
group [3]. However, while many younger infants are VAD,
supplementation studies have shown no beneficial effects
on child survival when given between 1–5 months [4].
Neonatal VA supplementation (NNVAS) has produced
conflicting findings. Giving 50,000 IU VA to infants within
the first month of life significantly reduced infant mor-
tality in South Asian settings (Indonesia, India and
Bangladesh) [5-7], but such beneficial effects have not
been replicated in an African setting. Trials conducted
in Guinea-Bissau and Zimbabwe have found no overall
effect of vitamin A supplementation (VAS) given at, or
just after birth, on infant survival [8,9]. A systematic re-
view of the literature commissioned by WHO identified 6
randomized controlled trials (RCTs) involving 42,508 in-
fants that evaluated NNVAS (given at < 1 month of age).
A meta-analysis of these trials suggested no overall effect
in infant mortality in the intervention group (pooled
relative risk 0.92, 95% CI 0.75 to 1.12, P = 0.393; I2 =
54.1%, P = 0.053) [10]. The available evidence however
is not enough to either accept or reject NNVAS as an
intervention with considerable potential for improving in-
fant survival. WHO therefore commissioned three new
large trials of NNVAS in Ghana, Tanzania and India [11]
with mortality as the primary outcome in conjunction
with two smaller mechanistic immunological trials in
Bangladesh and The Gambia. In conjunction with these
trials, a study on VA metabolism in the piglet model was
also commissioned.
Vitamin A plays an essential role the development of
healthy immune responses [12]. Substantive evidence
from animal (in vivo and in vitro) and human in vitro
studies indicates that VA and its metabolites (particularly
retinoic acid (RA)) have a powerful role in the regulation
of both innate and adaptive immune responses [13,14].
In terms of innate immune responses, this includes the
integrity of mucosal epithelia[15] and the numbers, differ-
entiation and cytokine secretion profiles of monocytes,
macrophages, natural killer cells and neutrophils [16,17].
With respect to adaptive immune response, it has been
postulated that VA has a role in thymic development and
maturation of thymocytes [18], therefore VAD may impair
thymic function, with resultant effects on the peripheral T
cell pool. Many studies have shown that VAS increases
the number of T cells, particularly the CD4+ subpopulation
and that it has a direct effect on cytokine production and T
cell activation [17,19,20]. Animal studies have demonstrated
that VA effects the helper T cell 1 (Th1)/Th2 balance, with
VAD inducing a shift in the immune response towards
Th1-cell-mediated immunity and VAS boosting Th2-type
responses [21]. In addition, VAS suppresses Th17 responses
and promotes regulatory T cell (Treg) responses [22-24];
whilst inducing gut-homing markers (α4β7 and CCR9) in
CD4+ and CD8+ T lymphocytes, Treg cells and B cells
[25-27]. Specific subsets of intestinal antigen-presenting
cells present in the lamina propria, such as dendritic cells
(DCs) and macrophages express RA synthesizing enzymes
(aldh1a1 and aldh1a2), and therefore have the capacity to
convert VA into RA (as reviewed in [28]). More recent data
has shown that although RA plays an important role in the
maintenance of intestinal tolerance and in immune homeo-
stasis, during infection or autoimmune inflammation, it has
the reciprocal role of promoting effector T cell responses
[29]. RA has also been demonstrated to stimulate B cell
maturation, activation and differentiation), and increase
primary and memory antibody responses [30]. A very
limited number of immunological studies have been
conducted on VAS in human neonates. A RCT con-
ducted in Guinea Bissau found no effect on NNVAS
and immune responses to BCG vaccine at 6 months of
age [31], however studies nested within this trial, ana-
lysed by sex, found that in boys less than 6 months of
age, VAS had a beneficial effect on non-rotavirus diar-
rhoea [32] and was also associated with less measles
hospitalisations and deaths [33]. Given such wide ran-
ging immunological effects and the uncertainty about
whether NNVAS is beneficial or not, this study set out
to investigate the effect of NNVAS in a West African
neonatal population.
Methods/design
Study design
This trial was designed to provide indicative data on the
immunological impact of NNVAS to infants born in a
peri-urban area of The Gambia; an area of moderate
VAD. Two hundred mother–infant pairs were enrolled in
a single centre, phase II, double-blind, RCT. Mother-
infant pairs were approached shortly after delivery, with
randomisation occurring within 48 hours of birth. A range
of immunological outcomes were examined up until the
17th week of life and participation continued for one year
to ensure that all Expanded Programme of Immunisation
(EPI) vaccines were administered including 100,000 IU
VA to infants at 6 months of age and 200,000 IU VA at
12 months. During this additional follow-up period, mor-
bidity and anthropometry data were collected. Recruit-
ment commenced in December 2011 and was completed
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in October 2012. The last study participant reached the
17th week of life in February 2013 and graduated from the
trial in October 2013. All field and laboratory staff
remained blinded throughout the trial. Following database
lock of the ‘immunology phase’ of the trial (data up to
the 17th week of life), the principal investigator (PI) was
partially unblinded to group level only; (not placebo/
intervention assignment). Data analysis is still ongoing.
Participants and study setting
Mother-infant pairs (n = 200) were recruited at the
Sukuta Health Centre; a government health clinic, in the
Western coastal region of The Gambia. The health
centre has a peri-urban catchment area ie: surrounding
an urban town with characteristics of a rural setting;
characterised by low income and crowded living condi-
tions. The Gambia has a population of 1.8 million of
which 57% reside in the urbanised coastal area [34].
There is a low adult HIV prevalence (1.5%)[35] and an
infant mortality rate of approximately 66.4 per 1,000 live
births [34]. Data from previous studies indicate a high
prevalence of VAD among women and children. In 2001
the Gambian National Nutrition Agency (NaNA) con-
ducted a nationwide survey of VAD, which demonstrated
over 70% moderate VAD (serum retinol < 0.70 μmol/L) in
pregnant and lactating mothers, infants and under 5 years
in most areas, including coastal regions [36]. More re-
cently, an RCT that examined the safety and efficacy of
early high-dose VAS in 220 rural Gambian infants indi-
cated a prevalence of 58% of VAD in cord blood [37].
The local community was sensitized to the study
through an open day organised at MRC Sukuta clinic and
through field workers known to the community. Attend-
ance at government antenatal clinics in Sukuta varies
greatly and is unregulated; however pictorial representa-
tion of the trials information sheet was displayed at the
antenatal clinic. Mothers delivering at the Government
health centre were approached shortly after delivery by a
trained MRC nurse or field worker. Those that were inter-
ested in participating in the trial had all details of the
study explained to them in their local language, covering
all aspects of the trial, as laid out in the information sheet.
Any questions that arose were answered by the nurse or
field worker, or referred to the PI for clarification. Subjects
were also offered the opportunity to speak to the PI or
study clinician if they wished. If the subject agreed to par-
ticipate, a short assessment of understanding was con-
ducted, which consisted of 8 true/false questions about
what participating in the trial entailed. Mothers who an-
swered all questions correctly were invited to complete
the informed consent form (ICF). Mothers that had a
maximum of 2 incorrect answers had the information
sheet re-explained to them. At the second attempt, if all
questions were answered correctly, mothers were invited
to complete the ICF. Mothers that were unable to answer
all the questions correctly at the second attempt were not
invited to complete the ICF. Depending on the level of
literacy, written informed consent was obtained through
either a signature or thumb print. In the case of illiterate
mothers, an impartial witness (government nurse) was
present throughout the consenting process and counter
signed the informed consent form.
Throughout the trial, all participants had access to free
clinical consultations at the Sukuta MRC clinic; essential
drugs were provided free of charge and if required, they
had access to the clinical services available at the main
MRC unit at the coast.
Trial administration and oversight
This trial was approved by the Joint Gambia Government/
Medical Research Council ethics committee (local ethics
committee (LEC); project number SCC1198), the London
School of Hygiene and Tropical Medicine (LSHTM) eth-
ics committee (application number A277 5697) and the
WHO ethics review committee (protocol ID RPC389).
Approval from The Republic of The Gambia Government
Ministry of Health and Social Welfare and The Republic
of The Gambia National Pharmaceutical Services Medi-
cine Board was granted prior to participant recruitment.
The trial was periodically monitored by the clinical trials
support office (CTSO), MRC Gambia unit, with a primary
role of monitoring adherence to the trial protocol and
ICH-GCP guidelines. In addition, quality assurance audits
were conducted by both the quality department, (MRC
Gambia unit) and the sponsor’s quality assurance manager
(LSHTM) to ensure adherence to the trial protocol and
ICH-GCP guidelines. A detailed structured review of
study implementation was conducted by WHO technical
staff on a site visit shortly after recruitment commenced.
The local safety monitor (LSM) (consultant paediatrician,
clinical services department, MRC Gambia unit) had the
primary role of independently monitoring all serious ad-
verse events (SAEs) (as defined by ICH-GCP guidelines)
and all adverse events (AEs) occurring within 72hs of sup-
plementation. The data safety monitoring board (DSMB)
was sponsored by WHO and monitored both adherence
to the trial protocol and supervised the progress of the
trial toward its objectives via interim analyses of selected
outcome data by randomization groups. The DSMB met a
total of five times and conducted interim analyses of the
safety data, pertaining to the occurrence of AE/SAEs. In
addition, reports on SAEs were submitted to the DSMB,
designated WHO officials, LSHTM quality assurance
manager, CTSO and LSM in real time. Stopping criteria
for the trial were as follows: (a) Increased mortality in one
group compared to the other defined as either (i) mortal-
ity 2 times higher in one group compared to the other, (ii)
rate exceeding 6 neonatal deaths per 100 subjects in either
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group, (iii) rate exceeding 11 infant deaths per 100 sub-
jects in either group); (b). Preponderance of evidence of
other side effects; (c) Overwhelming evidence of early
benefit in one group compared to the other.
Inclusion criteria and exclusion criteria
Inclusion criteria included singleton birth, birth weigh ≥
1,500 g, mothers over 18 years, residency within the study
area and administration of birth vaccinations and VAS
within 48hs of birth. Exclusion criteria were infants having
a congenital disease, a serious infection at birth or an in-
ability to feed (initially assessed by the lack of a suck re-
flex), mothers who were seriously ill at the time of
enrolment (defined as bed bound for more than 24 hs),
mother participating in other studies and/or mothers who
were known to be HIV infected. In cases where HIV status
of the mother was not known at birth, a subsequent posi-
tive test result at 1 week post-partum led to exclusion
before the six week time point (time of first bleed).
Randomisation and allocation
Randomization occurred within 48 hs of birth, once it has
been established that the neonate met all inclusion criteria
and that the mother had provided informed consent.
Randomization accommodated stratification by sex and
mean birth weight (over/under 3,150 g), to allow for later
analyses by sex and to allow enrolment of infants with a
range of nutritional status. The randomization lists was gen-
erated by WHO, using Stata, v11 (http://www.stata.com/
products/stb/journals/stb41.pdf, command “ralloc”, p.44).
Randomization was performed in blocks of four to ensure a
balance in sample size across groups over time. This com-
pensated for any potential seasonal effects on vaccine and
VA responses. Each neonate enrolled into the trial was given
the next available supplement from the box of supplements
that corresponded to their birth weight and sex grouping
(eg: female above 3,150 g; males below 3,150 g etc.).
Intervention
The VA capsules (soybean oil carrier with 50,000 IU reti-
nyl palmitate and minute quantities of vitamin E) and pla-
cebo (soybean oil without VA) were prepared by Strides
Arcolab Limited, (Bangalore, India). These capsules are
from the same batches prepared for the NNVAS mortality
trials [11]. Capsules and corresponding packaging (photo-
sensitive blister packs containing 2 identical capsules)
appeared identical for intervention and placebo. Within
each blister pack, one capsule was used for administration
to the neonate, whilst the other was used as either a back-
up capsule if the first dose was accidentally spilled, or for
randomly selected stability testing (conducted periodically
throughout the trial by an independent laboratory
(VITAS, Norway)). Blinded codes were assigned to each
blister pack by a designated WHO official in Geneva, with
the code held securely by the WHO official and two add-
itional independent custodians. Supplements were se-
curely stored in an air conditioned room (24°C) with the
temperature recoded daily. On each designated supple-
mentation day, four boxes of supplements were trans-
ported to the clinic in a cool box containing chilled cool
packs, (to ensure temperatures did not reach in excess of
30°C whilst in the field) with temperatures recorded peri-
odically. Oral supplementation was conducted by one of
two trained study staff and supervised by either the PI, or
a designated supervisor. The supplement was adminis-
tered by cutting the tapered end of the capsule with scis-
sors and squeezing the complete contents of the capsule
directly into the neonate’s mouth.
Study follow-up period
All infants were followed-up from birth to one year of age
and received their childhood vaccines according to the
recommended EPI schedule in The Gambia (Table 1). The
flow chart of the study is presented in Figure 1. For each
infant, two adverse event home visits were carried out by
trained nurses at 24 and 72 hs post-supplementation. Ex-
pected adverse events were bulging fontanelle, diarrhoea,
vomiting, fever, inability to suck or feed and convulsions.
In cases were infants were unwell, vital signs were re-
corded and the infant was immediately brought to the
MRC Sukuta clinic for review by the trial physician (or
MRC hospital ward staff if the trial physician was
unavailable).
Measurements and sample collection
Following delivery, infants were seen at the MRC Sukuta
clinic within 48hs of birth and at 1, 6, 8, 12, 16 and
17 weeks of age. Home visits were conducted for the two
post-supplementation AE visits, at three weeks of age (for
morbidity assessment) and at six weeks of age (+ 72 hs)
for tuberculin skin test (TST) readings. In a subset of 53
participants a modified relative dose response (MRDR)
test was administered at home at 17 weeks of age (prior to
Table 1 EPI Schedule in The Gambia During the First Year
of Life
Age (week) Vaccine
0 (within 48 hours of birth) BCG, HBV, OPV
8 Pentavalent, OPV, PCV-13
12 Pentavalent, OPV, PCV-13
16 Pentavalent, OPV, PCV-13
26 VAS (100,000 IU)
40 Measles, Yellow Fever, OPV
52 VAS (200,000 IU)
Key: BCG; bacillus Calmette-Guerin, OPV; oral poliovirus vaccine, HBV; hepatitis
B vaccine, Pentavalent (DTwP, Hib, HBV (DTwP: diptheria, tetanus, whole cell
pertussis; Hib: Haemophilus Influenza type b)), PCV-13; 13-valent pneumococcal
conjugate vaccine, VAS; vitamin A supplementation.
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the 17 week clinic visit). This test has been described pre-
viously [38] and is an accurate indicator of VA liver stores.
Table 2 details the data and sample collection schedule for
each visit. At all time points infant anthropometric
measurements were made using standard protocols
with regularly validated equipment, including weight,
length, head circumference and mid-upper arm circumfer-
ence (MUAC). At all trial visits, morbidity (including vital
signs) and breastfeeding practices since the previous visit
were assessed. Maternal anthropometric measurements
were taken after delivery and at 6, 12 and 17 weeks. A
demographic and socio-economic questionnaire was com-
pleted at the one week visit, along with questionnaires re-
garding the mothers feeding practices seven days prior to
delivery and her medical history during pregnancy. Venous
blood samples were collected from the mothers at the one
week visit (for HIV testing) and at six weeks (to assess
serum retinol status). Following their six week blood draw,
all mothers received 200,000 IU VAS as per Gambian
Government post-partum protocol. It was ensured that the
supplement was not given to the mothers prior to their six
week blood draw.
Trained study personnel administered EPI vaccines to
all infants, as per Gambian Government protocol (Table 1).
All study vaccines which were administered during the
immunological phase of the trial (first 17 weeks of life)
were acquired directly from the designated UNICEF man-
ufacturers with cold-chain managed thereafter by the
study team. For vaccination during the additional ‘EPI
follow-up’ phase of the trial (6, 9 and 12 months age), vac-
cines and supplements were acquired from the EPI
Department of the Gambia Government, and the cold-
chain managed thereafter by the local government health
clinic. At 6 and 17 weeks of age, a venous blood sample
was collected from infants for full blood count, ex vivo
flowcytometric analysis of B cells, Treg cells, DCs and T
cells, anti-hepatitis B antibody titre (17 week sample only),
MRDR test (subset of 17 week samples only), serum ret-
inol status and inflammatory markers. Residual aliquots
were banked for future analysis.
Mother-infant pairs assessed 
for eligibility shortly after birth
Exclusion criteria:
Multiple births
Birth weight <1,500g
Inability to feed (lack of suck reflex) 
Serious infection/congenital problems
Mother:  Serious Infection 
HIV positive 
<18 years
Enrolled in other study 
Living outside the study area
Follow-up until 17 weeks of age: Data and sample collection for immunological endpoints
Male
Delivery at Sukuta Health Centre
<3,150g 
Follow-up until 1 year: For the purpose of EPI administration, (with morbidity and anthropometry data collection only)
NNVAS or placebo NNVAS or placebo
Female
<3,150g 
NNVAS or placebo NNVAS or placebo
Enrolment and Randomization (within 48hs of birth)
Figure 1 Flow chart of the study design. Key: EPI; expanded programme of immunisation; NNVAS; neonatal vitamin A supplementation.
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Neonatal/infant thymus size was assessed sonographi-
cally at 1, 6, 12 and 17 weeks using a validated method
in which the transverse diameter of the thymus and the
saggital area of its largest lobe are multiplied to give a
volume-related thymic index (TI) [39]. In addition, DNA
extracted from peripheral blood mononuclear cells at
the 17 week time point were used for T cell receptor ex-
cision circles (TRECs) analysis as a further marker of
thymic function [40].
Trial outcomes
The primary endpoint of this trial is the frequency of circu-
lating Treg cells expressing gut homing receptors in infants
at 17 week post-supplementation; the null hypothesis being
that NNVAS will increase the frequency of gut homing
Treg cells compared to the control arm. Secondary analysis
will compare the following variables between trial arms;
thymus maturation (assessed at 1, 6, 12 and 17 weeks using
TI and TRECs analysis at 17 weeks) and enhanced B cell
immune responses, (assessed via ex vivo flow cytometric
analysis at 6 and 17 weeks (frequency and cell subtype)
along with Hepatitis B antibody responses at 17 weeks
post-supplementation). In addition to the primary and sec-
ondary outcomes listed on clinicaltrials.gov, the following
hypotheses were investigated: i) NNVAS diminishes the
TST response; ii) NNVAS decreases inflammatory
markers. Sample collection has been completed to ad-
dress the following hypotheses too, however due to
funding restrictions data are still pending; i) NNVAS
skews mycobacterial and recall antigen responses to-
wards a Th2 profile; ii) NNVAS diminishes Th1 and
Th17 reactivity to mycobacterial and recall antigens; iii)
NNVAS causes increased innate immune reactivity; iv)
NNVAS increases circulating immunoglobulin A (IgA)
in the mucosal immune compartment, especially oral
polio vaccine (OPV) specific IgA post-vaccination; v)
NNVAS decreases bacterial translocation, by improving
mucosal barrier function.
Analysis plan
All baseline data will be described using appropriate
summary statistics i.e. mean and standard deviation for
normally distributed variables and median and inter-
quartile range for non-normally distributed variables.
Data also of interest, although not part of the primary or
secondary analysis, are the comparison between trial arms
of serum retinol levels (indirectly measured via retinol
binding protein), MRDR values, anthropometry data (of
both infant and mother), morbidity and mortality, mother
feeding practices prior to delivery, infant feeding practices,
socio-economic status, demographic data and pregnancy
medical history. Ex vivo flow cytometric analysis of DCs
and T cell panels was also conducted. For the primary and
secondary analysis both linear regression (for continuous
outcomes such as Treg cells) and logistic regression (for
binary outcomes such as TST response) will be used to
quantify the difference between trial arms. The regression
models, where necessary, will allow for repeated measures
within individuals over time using random effects and all
relevant covariates will be taken into account. Model as-
sumptions will be checked to confirm reliable estimates
and appropriate transformations applied to the outcome
variable. The randomization is stratified by birth weight
and sex and so both will be taken into account for all ana-
lysis. Significance is defined as p < 0.05. All analysis will be
performed in Stata v12.1 (StataCorp LP, USA, http://www.
stata.com).
Sample size
A sample of size of 200 was based on previous similar
immunological studies carried out in the same cohort
[41], alongside logistical and financial factors. Knowledge
on the potential immunological sequelae of human
Table 2 Sample and data collection time points
Infant age (weeks)
Measurement 0* 1 3 6 8 12 16 17 26 40 52
EPI X X X X X X X
Thymic index X X X X
Venous bleed (Infant) X X
Venous bleed (Mothers) X X
Tuburculin skin test X
Modified relative dose response X
Anthropometry (Infant) X X X X X X X X X X
Anthropometry (Mother) X X X X
Morbidity X X X X X X X X X X X
*within 48hs of birth Note: Adverse event visits were carried out at 24 and 72 hours post-supplementation. Mothers’ venous bleed at 1 week was to determine
HIV status before the 6 week time point.
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NNVAS is so scarce that the foremost aim of this study
is to seek indicative data on aspects of immunity likely
to be affected by NNVAS which can then be subjected
to adequately powered investigations where power can
be calculated based on variances derived in this study
(and its Bangladeshi counterpart).
Discussion
The trials in The Gambia and Bangladesh will shed light
on the potential biological mechanisms by which NNVAS
modulates the human neonatal immune system. With the
animal metabolism study which has been run in parallel,
these three studies were designed to complement the large
mortality trials[11] which alongside existing data from
previous NNVAS trials (conducted in Indonesia,
Bangladesh, Nepal, India, Guinea-Bissau and Zimbabwe
[5-9,42]) will provide definitive information in formu-
lating global policy for this intervention.
Trial status
Ongoing; recruitment and follow-up is completed, partially
unblinded analysis is still ongoing.
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